The Patients' Access to Treatments Act (H.R. 4209) was introduced in the 112th Congress, which has adjourned.

It was reintroduced in the 113th Congress as H.R. 460.

If you weighed in on this bill, you can still voice your opinion on H.R. 460 — 113th Congress.

View Archived Comments on H.R. 4209 (112th) — 112th

View H.R. 4209 (112th) report

What’s your position on
The Patients' Access to Treatments Act

H.R. 4209: Patients’ Access to Treatments Act of 2012

Summary: To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. (More Info)

The Patients' Access to Treatments Act (H.R. 4209) was introduced in the 112th Congress, which has adjourned.

It was reintroduced in the 113th Congress as H.R. 460.

What POPVOX Users Say

POPVOX Nation:
62% Support
37% Oppose
(8 users)

View Report & Comments

5 users
3 users
order determined by social media popularity

Endorsing Organizations

The Leukemia & Lymphoma Society 1,048 Facebook fans 786 Twitter followers

Under many private insurance plans, patients with cancer continue to pay extremely high out-of-pocket costs because their prescribed medication is placed on a “specialty tier.” Specialty tiers allow plans to impose high coinsurance, in lieu of a co-payment, for expensive drugs, resulting in higher out-of-pocket spending for patients. This policy has a direct, negative impact upon patient access to needed medicines, and disproportionately affects those prescribed innovative therapies, which may offer greater effectiveness or fewer side effects than older options. Not only does this place a financial burden on patients, but it has also been shown to discourage adherence to ...

Read full position statement.